Curanex Pharmaceuticals Inc (CURX) — SEC Filings
Curanex Pharmaceuticals Inc (CURX) — 16 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 6 8-K, 6 S-1/A, 2 10-Q.
View Curanex Pharmaceuticals Inc on SEC EDGAR
Overview
Curanex Pharmaceuticals Inc (CURX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: Curanex Pharmaceuticals Inc. filed an 8-K on April 2, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an 8-K form, an exhibit (EX-99.1), and associated XBRL data. The company's mailing and business address is 2 Jericho
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 1 bearish, 12 neutral, 3 mixed. The dominant filing sentiment for Curanex Pharmaceuticals Inc is neutral.
Filing Type Overview
Curanex Pharmaceuticals Inc (CURX) has filed 6 8-K, 1 10-K, 2 10-Q, 6 S-1/A, 1 S-1 with the SEC between Oct 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of CURX's 15 recent filings, 4 were flagged as high-risk, 8 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $-15.3M |
| EPS | $-0.54 |
| Debt-to-Equity | 0.0 |
| Cash Position | $25.1M |
| Operating Margin | N/A |
| Total Assets | $28.3M |
| Total Debt | $0 |
Key Executives
- Jun Liu
- Mark Crone, Esq.
- Huan Lou, Esq.
- Joe Laxague, Esq.
- Mark Crone
- Huan Lou
- Joe Laxague
- Eleanor Osmanoff
- David Manno
Industry Context
Curanex operates in the rapidly expanding global market for inflammatory disease treatments, specifically focusing on botanical drugs. The phytomedicine market, valued at approximately $34 billion USD, presents a significant opportunity. However, this sector is also characterized by intense competition from established pharmaceutical giants and numerous emerging biotechs, all vying for market share with diverse therapeutic approaches.
Top Tags
sec-filing (5) · Pharmaceuticals (4) · IPO (4) · ipo (4) · pharmaceuticals (4) · 8-K (3) · Biotechnology (3) · Inflammatory Diseases (2) · 8-k (2) · disclosure (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK Number | 0002025942 | Identifies Curanex Pharmaceuticals Inc. in SEC filings. |
| Filing Date | 2026-04-02 | Date Curanex Pharmaceuticals Inc. filed this 8-K report. |
| Global Phytomedicine Market | $34B | Market size in 2022-2026, indicating significant growth potential for botanical drugs. |
| Shares Outstanding | 28,364,812 | As of March 30, 2026, reflecting the company's current equity structure. |
| IPO Date | 2025-08-27 | Date Curanex completed its initial public offering and began trading on Nasdaq. |
| Target IND Submission | 2026-Q4 | Planned quarter for submitting the Investigational New Drug application for ulcerative colitis. |
| Indications | 6 | Number of core indications Phyto-N is being developed for, including ulcerative colitis and COVID-19. |
| Years of Human Use | 30+ | History of Phyto-N's use in traditional Chinese medicine, providing a foundation for safety. |
| Dose Level | 6x | Highest dose tested in dogs during toxicology study, relative to proposed clinical dose, showing no adverse findings. |
| GMP Pilot-Scale Manufacturing | 2026-02 | Month Curanex completed a critical manufacturing milestone for Phyto-N. |
| Dose-Range Finding Study Completion | 2026-03 | Month Curanex announced successful completion of a key toxicology study. |
| Net Loss | $1,151,988 | for the nine months ended September 30, 2025, up from $215,567 in 2024 |
| Research & Development Expense | $679,574 | for the nine months ended September 30, 2025, up from $0 in 2024 |
| Net Proceeds from IPO | $13.24 million | received in August 2025 |
| Net Proceeds from Over-Allotment Option | $2.07 million | received in September 2025 |
Frequently Asked Questions
What are the latest SEC filings for Curanex Pharmaceuticals Inc (CURX)?
Curanex Pharmaceuticals Inc has 16 recent SEC filings from Oct 2024 to Apr 2026, including 6 8-K, 6 S-1/A, 2 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CURX filings?
Across 16 filings, the sentiment breakdown is: 1 bearish, 12 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Curanex Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Curanex Pharmaceuticals Inc (CURX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Curanex Pharmaceuticals Inc?
Key financial highlights from Curanex Pharmaceuticals Inc's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CURX?
The investment thesis for CURX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Curanex Pharmaceuticals Inc?
Key executives identified across Curanex Pharmaceuticals Inc's filings include Jun Liu, Mark Crone, Esq., Huan Lou, Esq., Joe Laxague, Esq., Mark Crone and 4 others.
What are the main risk factors for Curanex Pharmaceuticals Inc stock?
Of CURX's 15 assessed filings, 4 were flagged high-risk, 8 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Curanex Pharmaceuticals Inc?
Forward guidance and predictions for Curanex Pharmaceuticals Inc are extracted from SEC filings as they are enriched.